**SUMMARY REPORT FOR PUBLICATION**

**November 2019 Advisory board for Crysvita (burosumab) by Kyowa Kirin Limited**

The MHRA received a complaint via the Prescription Medicines Code of Practice Authority from an anonymous uncontactable source about an advisory board meeting held in Salzburg, Austria, on 25 June 2019 organised by Kyowa Kirin Limited. The complainant alleged that the meeting was more about Kyowa Kirin Limited promoting the benefits of Crysvita (burosumab).

MHRA reviewed the slides and associated materials for the meeting. The stated aim was to bring together a group of experts from different bone specialities to discuss long-term musculoskeletal outcomes associated with the management of children with X-linked hypophosphataemia. MHRA was very concerned about the impression given to the complainant but, based on the information available, did not uphold the complaint. The company made procedural improvements based on their internal investigation of the complaint.